The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Holland Venture en BOM investeren in CytoSMART: digitale microscopie in the cloud
Amsterdam/Tilburg, 13 juni 2016 - Investeringsmaatschappij Holland Venture investeert samen met de Brabantse Ontwikkelings Maatschappij (BOM) in CytoSMART Technologies. CytoSMART, opgericht in 2012 onder de naam CytoMATE, is een spin-off van de TU/e. Het bedrijf...
Holland Venture and BOM invest in CytoSMART: digital microscopic imaging in the cloud
Amsterdam/Tilburg, 13 June 2016 - Private equity firm Holland Venture and the Brabant Development Agency (BOM) are together investing in CytoSMART Technologies. Founded in 2012 under the name CytoMATE, CytoSMART is a spin-off of Eindhoven University of Technology...
Humeca opent officieel zusterbedrijf Humeca, Inc. in de Verenigde Staten
De opening volgt op een gestage groei van de vraag en het aanbod van hun producten wereldwijd en stelt Humeca in staat om hun distributienetwerk in de Verenigde Staten uit te breiden. De huidtransplantatie producten zijn levensreddend voor de behandeling van...
Humeca officially launches sister company Humeca, Inc. in the USA
Amsterdam, 12 februari 2016 - The launch follows a steady growth in demand and supply of their products worldwide and enables Humeca to expand their distribution network in the United States. The skin grafting products are life-saving for the treatment of burn...
Holland Venture investeert fors in groei marketingtechnologiebedrijf Relay42
Amsterdam, 8 december 2015 – Investeringsmaatschappij Holland Venture en de voormalige topmanager van Booking.com investeren gezamenlijk enkele miljoenen in de Nederlandse datamanagementspecialist Relay42. Met het innovatieve datamanagementplatform van Relay42 kunnen...
Holland Venture provides substantial investment to marketing technology company Relay42
Amsterdam, December 8th 2015 – Holland Venture and a former Board Executive of Booking.com have invested several millions of euros in the Dutch data management specialist Relay42. Marketers use Relay42’s innovative data management platform to coordinate the customer...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl